Data from clinical trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue SUPPL. 1, 2005, Pages

  Catanzaro, Linda M ^a   Morse, Gene D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CAFFEINE; DELAVIRDINE; DEXTROMETHORPHAN; EFAVIRENZ; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; NORETHISTERONE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; OXAZEPAM; RITONAVIR; WARFARIN; ZIDOVUDINE;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MEGADOSE; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 18244397952     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000167036.48772.c8     Document Type: Conference Paper

References (17)

1. Gram TE, Gillette JR. The role of sex hormones in the metabolism of drugs and other foreign compounds by hepatic microsomal enzymes. In: Salhanick HA, Kipnis DM, Vande Wiele RL, eds. Metabolic Effects of Canadal Hormones and Contraceptive Steroids. New York: Plenum Press; 1969: 86-94.
2. Joshi AS, Fiske WD, Benedek IH, et al. Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and EE in healthy female volunteers. Presented at 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 1-5 February 1998.
3. Mildvan D, Yarish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and EE/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr. 2002; 29:471-477.
4. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on pharmacokinetics of EE in healthy female volunteers. Br J Clin Pharmacol. 1998; 46:111-116.
5. Rescriptor® package insert. Agouron Pharmaceuticals; June 2001.
6. Agenerase® package insert. GlaxoSmithKline; October 2002.
7. Reyataz® package insert. Bristol-Meyers Squibb; June 2003.
8. Crixivan® package insert. Merck and Co; January 2002.
9. Kaletra™ package insert. Abbott Laboratories; January 2002.
10. Viracept® package insert. Agouron Pharmaceuticals; November 2001.
11. Fortovase®/Invirase® package insert. Roche Laboratories; July 2002.
12. Thevanayagam L, Hayashi S, Watts H, et al. The impact of gender and contraceptive therapy on the pharmacokinetics of plasma and intracellular zidovudine. Presented at 101st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Los Angeles, CA, 14-18 March 2000.
13. Delfraissy JF. Management of patients infected by the human immunodeficiency virus (HIV). Report of an expert group. Medecine-Sciences, Flammarion; 2002.
14. Fotherby K. Interactions with oral contraceptives. Am J Obstet Gynecol. 1990; 163:2153-2159.
15. Streetman DS, Bleakley JF, Kim JS. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000; 68:375-383.
16. Shelepova T, Nafziger AN, Victory J, et al. Effect of oral contraceptives (OCs) on drug metabolizing enzymes (DMEs) as measured by the validated cooperstown 5+1 cocktail (5+1). Clin Pharmacol Ther. 2003; 73 (Suppl.):P14-P14.
17. Zhang Y, Shelepova T, Godri K, et al. Lack of correlation between CYP3A probes and midazolam in healthy Caucasian women on or off oral contraceptives (OCs). Clin Pharmacol Ther. 2003; 73 (Suppl.):P15-P15.